title: Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia.
abstract: Tardive dyskinesia (TD) is a delayed and potentially irreversible motor complication arising in patients chronically exposed to antipsychotic drugs. As several modern (so-called atypical) antipsychotic drugs are common offenders, combined with the widening clinical indications for prescription as well as exposure of vulnerable individuals, TD will remain a significant drug-induced unwanted side effect. In addition, the pathophysiology of TD remains elusive and therapeutics are difficult. Based on rodent experiments, we have previously shown that the transcriptional factor Nur77 (also known as nerve growth factor inducible gene B or Nr4a1) is induced in the striatum following antipsychotic drug exposure as part of a long-term neuroadaptive process. To confirm this, we exposed adult capuchin (Cebus apella) monkeys to prolonged treatments with haloperidol (median 18.5 months, N = 11) or clozapine (median 6 months, N = 6). Six untreated animals were used as controls. Five haloperidol-treated animals developed mild TD movements similar to those found in humans. No TD was observed in the clozapine group. Postmortem analysis of Nur77 expression measured by in situ hybridization revealed a stark contrast between the two drugs, as Nur77 mRNA levels in the caudate-putamen were strongly upregulated in animals exposed to haloperidol but were spared following clozapine treatment. Interestingly, within the haloperidol-treated group, TD-free animals showed higher Nur77 expression in putamen subterritories compared with dyskinetic animals. This suggests that Nur77 expression might be associated with a reduced risk of TD in this experimental model and could provide a novel target for drug intervention.
authors.affiliation: Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.
authors.forename: Souha
authors.initials: S
authors.lastname: Mahmoudi
authors.forename: Pierre J
authors.initials: PJ
authors.lastname: Blanchet
authors.forename: Daniel
authors.initials: D
authors.lastname: Lévesque
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D002428:Cebus; D003024:Clozapine / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology*; D009069:Movement Disorders / Q000378:metabolism* / Q000503:physiopathology; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1 / Q000235:genetics / Q000378:metabolism*; D011699:Putamen / Q000187:drug effects / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects; D015854:Up-Regulation
chemical_list: D014150:Antipsychotic Agents; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D012333:RNA, Messenger; D003024:Clozapine; D006220:Haloperidol
keywords: Nr4a1; abnormal involuntary movements; antipsychotic drug; clozapine; monkey; transcription factor
references.citation: Trends Neurosci. 2007 Jan;30(1):22-30
references.pmid: 17134767
references.citation: Behav Brain Funct. 2012 Mar 09;8:12
references.pmid: 22404856
references.citation: Nat Clin Pract Gastroenterol Hepatol. 2006 Mar;3(3):138-48
references.pmid: 16511548
references.citation: Neuroscience. 2000;96(3):451-74
references.pmid: 10717427
references.citation: Neuroscience. 2001;106(1):117-28
references.pmid: 11564422
references.citation: Mov Disord. 2006 May;21(5):589-98
references.pmid: 16532448
references.citation: J Neurochem. 2000 Oct;75(4):1694-702
references.pmid: 10987852
references.citation: J Am Geriatr Soc. 2005 Aug;53(8):1374-9
references.pmid: 16078964
references.citation: Int Rev Neurobiol. 2011;98:187-210
references.pmid: 21907088
references.citation: Eur J Pharmacol. 2003 Feb 21;462(1-3):133-8
references.pmid: 12591105
references.citation: Trends Neurosci. 1991 Jan;14(1):21-7
references.pmid: 1709528
references.citation: J Clin Psychiatry. 2010 Apr;71(4):463-74
references.pmid: 20156410
references.citation: Neuropsychopharmacology. 2004 Feb;29(2):335-46
references.pmid: 14603264
references.citation: Prog Neurobiol. 1996 Oct;50(2-3):83-107
references.pmid: 8971979
references.citation: J Clin Pharmacol. 2008 Mar;48(3):379-84
references.pmid: 18223146
references.citation: Neurobiol Dis. 2009 Oct;36(1):213-22
references.pmid: 19635563
references.citation: J Pharmacol Exp Ther. 2005 Apr;313(1):460-73
references.pmid: 15615863
references.citation: Schizophr Bull. 1992;18(4):701-15
references.pmid: 1359633
references.citation: Lancet. 2009 Jan 3;373(9657):31-41
references.pmid: 19058842
references.citation: Biol Psychiatry. 2004 Mar 1;55(5):457-63
references.pmid: 15023572
references.citation: Synapse. 2001 Feb;39(2):122-32
references.pmid: 11180499
references.citation: Proc Natl Acad Sci U S A. 1994 May 10;91(10):4353-6
references.pmid: 8183912
references.citation: Eur Arch Psychiatry Clin Neurosci. 2007 Apr;257(3):169-72
references.pmid: 17149539
references.citation: Psychopharmacology (Berl). 1979 Jun 21;63(3):195-8
references.pmid: 39307
references.citation: Brain Res Brain Res Rev. 1998 Dec;28(3):370-490
references.pmid: 9858769
references.citation: Mol Psychiatry. 2005 Jan;10(1):79-104
references.pmid: 15289815
references.citation: Psychiatr Genet. 2010 Feb;20(1):39-43
references.pmid: 20010315
references.citation: Neurosci Biobehav Rev. 2002 May;26(3):361-80
references.pmid: 12034136
references.citation: Biol Psychiatry. 2004 Oct 1;56(7):522-6
references.pmid: 15450789
references.citation: Psychopharmacology (Berl). 1999 Jun;144(3):189-97
references.pmid: 10435384
references.citation: Genes Dev. 1995 Apr 1;9(7):769-82
references.pmid: 7705655
references.citation: Brain Res Brain Res Rev. 1995 Jan;20(1):91-127
references.pmid: 7711769
references.citation: Int J Neuropsychopharmacol. 2012 May;15(4):509-21
references.pmid: 21524335
references.citation: Mol Cells. 2002 Dec 31;14(3):323-31
references.pmid: 12521293
references.citation: JAMA. 2003 Nov 26;290(20):2693-702
references.pmid: 14645311
references.citation: Arch Gen Psychiatry. 2006 Oct;63(10):1079-87
references.pmid: 17015810
references.citation: Brain Res. 2000 Apr 28;863(1-2):112-9
references.pmid: 10773199
references.citation: Front Neuroanat. 2011 Apr 20;5:26
references.pmid: 21541304
references.citation: Synapse. 1996 Jul;23(3):182-91
references.pmid: 8807746
references.citation: Br J Psychiatry. 2012 May;200(5):387-92
references.pmid: 22442101